Novo Nordisk has completed its acquisition of three manufacturing sites from Novo Holdings A/S.
The completion follows the finalisation of Novo Holdings’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US).
The agreement to acquire the three manufacturing sites was announced on 5 February 2024.
“We are very pleased with the completion of the acquisition. The three sites will expand our manufacturing capacity at scale and speed, while complementing our ongoing significant
internal supply chain expansions."
"The acquisition will enable us to reach significantly more people living with serious chronic diseases,” said Lars Fruergaard Jørgensen, President and Chief Executive Officer of Novo Nordisk.
